"For clinicians working with these patients, it’s important to understand the evolving role of immune checkpoint blockade with anti-PD1 therapy." ---- Kevin Emerick, MD In recent years, however, ...

Regeneron has fleshed out additional positive data for blockbuster immunotherapy Libtayo (cemiplimab) as an adjuvant therapy in high-risk cutaneous squamous cell carcinoma (CSCC), as rival PD-1 ...

Currently, there is no treatment approved for resectable cutaneous squamous cell carcinoma (cSCC), nor do we have biomarkers to predict treatment response, noted Neil D. Gross, MD, FACS, head and neck ...

TARRYTOWN, N.Y. - The U.S. Food and Drug Administration has approved Regeneron Pharmaceuticals’ (NASDAQ:REGN) Libtayo (cemiplimab-rwlc) as an adjuvant treatment for adult patients with cutaneous ...